March 2022 Legislative & Regulatory Briefing; AMCP Legislative Agenda 2022 and Beyond Webinar –Thursday, April 7; AMCP Signals Support for Legislative Priorities; AMCP Supports Authorization for Pharmacists to OrderCOVID-19 Antivirals; AMCP Responds to Part D Proposed Rule; AMCP is a Healthy People 2030 Champion.
June 2022 News & Views: There’s Still Time to Register for the AMCP Summit and Corresponding Satellite Symposia; Partnership Forum Summary on High Investment Medications Now Available; View the Updated Pharmacy Pay-for-PerformancePrinciples.
In 2016, AMCP made pre-approval information exchange (PIE) a legislative priority recognizing its vital importance to patients. On June 8, 2022, the U.S. House of Representatives passed the PIE Act of 2022. Learn more about PIE as a legislative priority for AMCP.
Partnership Forum: This forum identified challenges and payer needs related to the evidence for digital therapeutics. The forum explored the current market space for digital therapeutics including the evidence for the products, place in therapy, monitoring or utilization metrics and barriers that patients face in obtaining therapies.
On May 18, 2022, AMCP hosted Legislative Days where AMCP members and the AMCP Policy and Government Relations team met virtually with U.S. Senators and Representatives to advocate for AMCP's top policy priorities. Learn more about the role Legislative Days plays in achieving our mission to improve patient health by ensuring access to high-quality, cost-effective medications and other therapies.
By Jennifer Mathieu, Vice President, Policy and Government Relations • 6/15/22
On June 7, AMCP joined a pharmacy stakeholder letter to the Department of Health and Human Services (HHS) requesting clarification that pharmacies will maintain personnel flexibilities granted under the PREP Act emergency declaration through October 1, 2024.
On June 9, AMCP submitted comments to CMS on the 2022 Healthcare Common Procedure Coding System (HCPCS) Public Meeting. AMCP applauds CMS's efforts to standardize coding and billing practices for prescription digital therapeutics (PDTs), and recommends that CMS create additional codes to cover the full range of PDTs.